Danis Pharma

Danis Pharma has been active since 1999 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €784,088 and a net result of €71,707. Equity is growing by ~15.3% per year across the filed fiscal years. Its solvency ranks better than 95% of 12331 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).